[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Bronte, V., Brandau, S., Chen, S., Colombo, M.P., Frey, A.B., Greten, T.F., et al. (2016) Recommendations for Myeloid-Derived Suppressor Cell Nomenclature and Characterization Standards. Nature Communications, 7, Article No. 12150. https://doi.org/10.1038/ncomms12150
|
[3]
|
Gabrilovich, D.I., Bronte, V., Chen, S., Colombo, M.P., Ochoa, A., Ostrand-Rosenberg, S., et al. (2007) The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Research, 67, 425. https://doi.org/10.1158/0008-5472.can-06-3037
|
[4]
|
陈虹燕, 郭红. MDSCs与肿瘤微环境[J]. 免疫学杂志, 2015, 31(11): 996-1001.
|
[5]
|
Ioannou, M., Alissafi, T., Lazaridis, I., Deraos, G., Matsoukas, J., Gravanis, A., et al. (2012) Crucial Role of Granulocytic Myeloid-Derived Suppressor Cells in the Regulation of Central Nervous System Autoimmune Disease. The Journal of Immunology, 188, 1136-1146. https://doi.org/10.4049/jimmunol.1101816
|
[6]
|
Choi, J., Suh, B., Ahn, Y., Kim, T.M., Lee, J., Lee, S., et al. (2011) CD15+/CD16low Human Granulocytes from Terminal Cancer Patients: Granulocytic Myeloid-Derived Suppressor Cells That Have Suppressive Function. Tumor Biology, 33, 121-129. https://doi.org/10.1007/s13277-011-0254-6
|
[7]
|
Khan, A.N.H., Emmons, T.R., Wong, J.T., Alqassim, E., Singel, K.L., Mark, J., et al. (2020) Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research, 8, 819-828. https://doi.org/10.1158/2326-6066.cir-19-0556
|
[8]
|
Sinha, P., Clements, V.K., Fulton, A.M. and Ostrand-Rosenberg, S. (2007) Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells. Cancer Research, 67, 4507-4513. https://doi.org/10.1158/0008-5472.can-06-4174
|
[9]
|
Gabrilovich, D.I. and Nagaraj, S. (2009) Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nature Reviews Immunology, 9, 162-174. https://doi.org/10.1038/nri2506
|
[10]
|
Sharma, M.D., Rodriguez, P.C., Koehn, B.H., Baban, B., Cui, Y., Guo, G., et al. (2018) Activation of P53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 48, 91-106.E6. https://doi.org/10.1016/j.immuni.2017.12.014
|
[11]
|
刘秋燕, 曹雪涛. MDSCs与肿瘤免疫逃逸[J]. 中国肿瘤生物治疗杂志, 2009, 16(4): 319-324.
|
[12]
|
Szefel, J., Danielak, A. and Kruszewski, W.J. (2019) Metabolic Pathways of L-Arginine and Therapeutic Consequences in Tumors. Advances in Medical Sciences, 64, 104-110. https://doi.org/10.1016/j.advms.2018.08.018
|
[13]
|
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., et al. (2018) Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Frontiers in Immunology, 9, Article 398. https://doi.org/10.3389/fimmu.2018.00398
|
[14]
|
Talmadge, J.E. and Gabrilovich, D.I. (2013) History of Myeloid-Derived Suppressor Cells. Nature Reviews Cancer, 13, 739-752. https://doi.org/10.1038/nrc3581
|
[15]
|
Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2014) PD-L1 Is a Novel Direct Target of HIF-1α, and Its Blockade under Hypoxia Enhanced MDSC-Mediated T Cell Activation. Journal of Experimental Medicine, 211, 781-790. https://doi.org/10.1084/jem.20131916
|
[16]
|
Roth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., et al. (2018) Immunosuppression Mediated by Myeloid-Derived Suppressor Cells (MDSCs) during Tumour Progression. British Journal of Cancer, 120, 16-25. https://doi.org/10.1038/s41416-018-0333-1
|
[17]
|
Kumar, V., Patel, S., Tcyganov, E. and Gabrilovich, D.I. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends in Immunology, 37, 208-220. https://doi.org/10.1016/j.it.2016.01.004
|
[18]
|
樊慧婷, 林洪生. 髓源抑制性细胞与恶性肿瘤的研究进展[J]. 现代肿瘤医学, 2020, 28(12): 2150-2154.
|
[19]
|
Lechner, M.G., Megiel, C., Russell, S.M., Bingham, B., Arger, N., Woo, T., et al. (2011) Functional Characterization of Human CD33+ and CD11B+ Myeloid-Derived Suppressor Cell Subsets Induced from Peripheral Blood Mononuclear Cells Co-Cultured with a Diverse Set of Human Tumor Cell Lines. Journal of Translational Medicine, 9, Article No. 90. https://doi.org/10.1186/1479-5876-9-90
|
[20]
|
Sasano, T., Mabuchi, S., Kozasa, K., Kuroda, H., Kawano, M., Takahashi, R., et al. (2018) The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations. Clinical Cancer Research, 24, 4018-4029. https://doi.org/10.1158/1078-0432.ccr-17-2472
|
[21]
|
Yokoi, E., Mabuchi, S., Komura, N., Shimura, K., Kuroda, H., Kozasa, K., et al. (2019) The Role of Myeloid-Derived Suppressor Cells in Endometrial Cancer Displaying Systemic Inflammatory Response: Clinical and Preclinical Investigations. OncoImmunology, 8, e1662708. https://doi.org/10.1080/2162402x.2019.1662708
|
[22]
|
Mabuchi, S. and Sasano, T. (2021) Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers. Cells, 10, Article 1073. https://doi.org/10.3390/cells10051073
|
[23]
|
Mabuchi, S., Matsumoto, Y., Kawano, M., Minami, K., Seo, Y., Sasano, T., et al. (2014) Uterine Cervical Cancer Displaying Tumor-Related Leukocytosis: A Distinct Clinical Entity with Radioresistant Feature. JNCI Journal of the National Cancer Institute, 106, dju147. https://doi.org/10.1093/jnci/dju147
|
[24]
|
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S. and Amant, F. (2014) Mapping the Immunosuppressive Environment in Uterine Tumors: Implications for Immunotherapy. Cancer Immunology, Immunotherapy, 63, 545-557. https://doi.org/10.1007/s00262-014-1537-8
|
[25]
|
周敏. 宫颈癌患者外周血和宫颈组织中髓源性抑制细胞的检测及意义[D]: [硕士学位论文]. 镇江: 江苏大学, 2016.
|
[26]
|
杜婷. 髓源性抑制细胞MDSC在宫颈癌外周血中的表达及其临床意义[D]: [硕士学位论文]. 苏州: 苏州大学, 2016.
|
[27]
|
Kozasa, K., Mabuchi, S., Matsumoto, Y., Kuroda, H., Yokoi, E., Komura, N., et al. (2019) Estrogen Stimulates Female Cancer Progression by Inducing Myeloid-Derived Suppressive Cells: Investigations on Pregnant and Non-Pregnant Experimental Models. Oncotarget, 10, 1887-1902. https://doi.org/10.18632/oncotarget.26711
|
[28]
|
Gabrilovich, D.I. and Nagaraj, S. (2009) Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nature Reviews Immunology, 9, 162-174. https://doi.org/10.1038/nri2506
|
[29]
|
梁云. 子宫颈癌新辅助化疗组织学疗效评价及相关免疫因素的研究[D]: [博士学位论文]. 杭州: 浙江大学, 2017.
|
[30]
|
Veglia, F., Sanseviero, E. and Gabrilovich, D.I. (2021) Myeloid-Derived Suppressor Cells in the Era of Increasing Myeloid Cell Diversity. Nature Reviews Immunology, 21, 485-498. https://doi.org/10.1038/s41577-020-00490-y
|
[31]
|
徐鑫, 马斌, 丁建霞, 等. 髓源性抑制细胞对肿瘤的免疫抑制及靶向免疫治疗研究进展[J]. 江苏大学学报(医学版), 2021, 31(3): 272-276.
|
[32]
|
Iclozan, C., Antonia, S., Chiappori, A., Chen, D. and Gabrilovich, D. (2013) Therapeutic Regulation of Myeloid-Derived Suppressor Cells and Immune Response to Cancer Vaccine in Patients with Extensive Stage Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 62, 909-918. https://doi.org/10.1007/s00262-013-1396-8
|
[33]
|
邢凯, 刘苗. 靶向髓源抑制性细胞的肿瘤免疫治疗研究进展[J]. 河北医科大学学报, 2022, 43(6): 740-745.
|
[34]
|
董秀丽, 马爱兰, 魏立. 放疗联合吉西他滨治疗中晚期宫颈癌患者疗效及对转移复发的影响[J]. 临床心身疾病杂志, 2022, 28(1): 63-66.
|
[35]
|
蒋欢欢, 鲁智敏, 朱梦婷, 等. 宫颈癌组织内骨髓来源抑制性细胞频率与患者预后的关系[J]. 标记免疫分析与临床, 2021, 28(5): 822-825.
|
[36]
|
Mayadev, J., Nunes, A.T., Li, M., Marcovitz, M., Lanasa, M.C. and Monk, B.J. (2020) CALLA: Efficacy and Safety of Concurrent and Adjuvant Durvalumab with Chemoradiotherapy versus Chemoradiotherapy Alone in Women with Locally Advanced Cervical Cancer: A Phase III, Randomized, Double-Blind, Multicenter Study. International Journal of Gynecologic Cancer, 30, 1065-1070. https://doi.org/10.1136/ijgc-2019-001135
|
[37]
|
张颖, 吴月玲. 宫颈癌的免疫治疗: 精准医学的到来[J]. 实用医学杂志, 2022, 38(15): 1856-1859.
|